Perspective Therapeutics Dirección

Dirección controles de criterios 1/4

El CEO de Perspective Therapeutics' es Thijs Spoor , nombrado en Feb 2023, tiene una permanencia de 1.33 años. compensación anual total es $1.46M, compuesta por 34.7% salario y 65.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de $214.61K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 1.3 años, respectivamente.

Información clave

Thijs Spoor

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	34.7%
Permanencia del CEO	1.3yrs
Participación del CEO	0.03%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	1.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thijs Spoor en comparación con los beneficios de Perspective Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$1m	US$506k	-US$37m

Compensación vs. Mercado: La compensación total de Thijs($USD1.46M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD3.39M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Thijs con los resultados de la empresa.

CEO

Thijs Spoor (52 yo)

1.3yrs

Permanencia

US$1,458,996

Compensación

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Spoor	CEO & Director	1.3yrs	US$1.46m	0.031% $ 198.2k
Jonathan Hunt	CFO & Co-Principal Financial Officer	5.5yrs	US$1.17m	0.053% $ 343.6k
Markus Puhlmann	Chief Medical Officer	1.3yrs	US$900.09k	0.20% $ 1.3m
Shane Cobb	Executive Vice President of Operations	less than a year	sin datos	sin datos
Mark Austin	VP of Finance	6.9yrs	sin datos	0.012% $ 80.2k
Michael Schultz	Chief Science Officer	no data	sin datos	2.2% $ 14.2m
Andrew Bright	Executive Vice President of Brachytherapy	1.2yrs	sin datos	sin datos
Amos Hedt	Chief Business Strategy Officer	no data	sin datos	sin datos
Frances Johnson	Chief Innovation Officer	no data	sin datos	2.2% $ 14.2m
David Hauser	Senior Vice President of Clinical Operations	no data	sin datos	sin datos

1.3yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CATX no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Spoor	CEO & Director	1.3yrs	US$1.46m	0.031% $ 198.2k
Robert Williamson	Independent Director	1.3yrs	US$320.06k	0.063% $ 408.2k
Frank Morich	Independent Director	1.3yrs	US$320.06k	sin datos
Heidi Henson	Independent Director	less than a year	US$390.70k	sin datos
Lori Holmes-Woods	Chairperson of the Board	6yrs	US$671.73k	0.24% $ 1.6m

1.3yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de CATX no se considera experimentada (1.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Perspective Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Chief Medical Officer recently bought US$140k worth of stock

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

Recent updates

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought US$140k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Second quarter 2023 earnings released

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Chairperson of the Board exercised options to buy US$129k worth of stock.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Isoray, Inc. to Report Q4, 2022 Results on Sep 28, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Isoray, Inc. to Report Q3, 2022 Results on May 10, 2022

Price target decreased to US$1.47

Insufficient new directors

Consensus EPS estimates fall by 15%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CEO & Director exercised options to buy US$64k worth of stock.

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.016 loss per share (vs US$0.01 loss in 1Q 2021)

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad